1887
Volume 2022 Number 1
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Dapagliflozin has been shown to reduce the risk of heart failure hospitalization and cardiovascular mortality in patients with heart failure with reduced ejection fraction (HFrEF).1,2 This work aims to determine the cost-effectiveness of dapagliflozin added to standard therapy versus standard therapy alone in patients with HFrEF, regardless of the presence or absence of type 2 diabetes mellitus (T2DM). A lifetime Markov model was constructed to compare the health outcomes and costs of dapagliflozin added to standard therapy versus standard therapy alone from a Qatari public healthcare perspective (Figure 1).2 The cohort is comprised of HFrEF patients with left ventricular ejection fraction (LVEF) ≤ 40%, and New York Heart Association (NYHA) class II–IV with an average age of 65 years, based on Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) trial (Table 1).1,2 The model consisted of three health states: ‘stable’, ‘hospitalization for heart failure’, and ‘dead’. Clinical inputs were derived from the results of DAPA-HF trial and costs, and utilities were estimated from published sources as well as publicly available sources in Qatar.3 The main outcome was the incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year gained (QALY). All outcomes and costs were discounted at a rate of 3% annually. Sensitivity analyses were conducted to confirm the robustness of the results. The study was based on published data; therefore ethics approval was not required. Dapagliflozin added to standard care prevented 112 heart failure hospitalization and resulted in an additional cost of QAR 33,890 (USD 9,309). This equated to an ICER of QAR 101,763 (USD 27,951) per QALY gained, below the US willingness-to-pay threshold of USD 150,000 per QALY gained. Sensitivity analyses showed the findings to be robust.  Dapagliflozin in addition to standard care appears to be a cost-effective strategy for patients with HFrEF, regardless of the presence or absence of T2DM.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.qhc.62
2021-12-01
2022-12-04
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/1/jemtac.2022.qhc.62.html?itemId=/content/journals/10.5339/jemtac.2022.qhc.62&mimeType=html&fmt=ahah

References

  1. Krittayaphong R, Permsuwan U. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. International Journal of Cardiology. 2021 Jan 1; 322;: 183–190.
    [Google Scholar]
  2. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21; 381:(21):1995–2008.
    [Google Scholar]
  3. Di Tanna GL, Urbich M, Wirtz HS, et al. Health State Utilities of Patients with Heart Failure: A Systematic Literature Review. Pharmacoeconomics. 2021 Feb; 39:(2):211–229. doi: 10.1007/s40273-020-00984-6.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.qhc.62
Loading
/content/journals/10.5339/jemtac.2022.qhc.62
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): Cost-effectivenessDapagliflozinDiabetesHeart failure and Qatar

Most Cited This Month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error